cas: 3258-02-4 N(4)-hydroxycytidine EIDD-1931

cas: 3258-02-4 N(4)-hydroxycytidine EIDD-1931

N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2

N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.1,2 N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.5 It has shown antiviral activity against Venezuelan equine encephalitis virus,1 and the human coronavirus HCoV-NL63 in vitro.4 N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.3 It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.2 In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.6 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.3 The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.3

N4-Hydroxycytidine (3258-02-4) was originally identified as a mutagen effecting AT to GC base-pair transitions.1 It has also been found to have antiviral properties against a broad range of viruses including hepatitis C2, norovirus3, Ebola virus4, Chikungunya virus5, influenza and respiratory syncytial viruses6, and importantly, coronaviruses.7,8 N4-hydroxycytidine is the active molecule in the antiviral pro-drug clinical candidate EIDD-2801